Rabbit anti-Human ATRX Monoclonal Antibody | anti-ATRX antibody

ATRX (RBT-ATRX)

Cat. Num. AAA59355

• Reactivity: Human
• Synonyms: ATRX, Antibody; ATRX (RBT-ATRX); atrx; anti-atrx; alpha-thalassemia mental retardation syndrome X-linked; anti-ATRX antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: IgG
• Clone Number: RBT-ATRX
• Form/Format: Paraffin, Frozen; ATRX is a rabbit monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH7.5, containing BSA and sodium azide as a preservative.

• Immunogen: Recombinant human ATRX protein.
• Control: Breast, Colon, Fallopian Tube, Brain, Tonsil, Transitional Cell Carcinoma, T Cell Lymphoblastic Lymphoma
• Localization: Nuclear
• Preparation and Storage: Store at 2-8 degree C (Control Slides: Store at 20-25 degree C)

IHC (Immunohiostchemistry)

(ATRX Antibody Immunohistochemistry on an FFPE Astrocytoma Tissue)

Dilution Info

Related Product Information for anti-ATRX antibody

alpha-thalassemia/mental retardation syndrome X-linked (ATRX) gene is located on chromosome Xq21.1. ATRX is involved in many fundamental cellular processes such as transcription, replication, DNA repair and recombination. Germline mutations of ATRX have been found to cause the complex genetic disorder called Alpha-Thalassemia mental retardation syndrome. Somatic mutations, deletions, and altered ATRX expression levels were found to be prevalent in several cancer types. A study reported the loss of ATRX expression was found to be a prognostic marker for chromosome instability in pancreatic neuroendocrine tumors. There is also evidence that highlights the role of ATRX as a biomarker in breast cancer in which ATRX expression was significantly associated with tumor grade.
Mutation/loss of ATRX antibody expression has been described in anaplastic gliomas. A study explored the role of ATRX status in the molecular classification of anaplastic gliomas and its impact on survival. Loss of ATRX antibody expression was detected in 45 % of anaplastic astrocytomas (AA), 27 % of anaplastic oligoastrocytomas (AOA) and 10 % of anaplastic oligodendrogliomas (AO). Survival analysis showed a marked separation of IDH mutant astrocytic tumors into two groups based on ATRX status: tumors with ATRX loss had a significantly better prognosis. Another recent study analyzed the use of ATRX, IDH and 1p/19q codeletion in a series of astrocytomas, oligodendrogliomas, oligoastrocytomas and glioblastomas and presented an algorithm based on stepwise analysis with initial immunohistochemistry for ATRX and IDH1-R132H followed by 1p/19q analysis, then by IDH sequencing, which reduces the number of molecular analyses and has a far better association with patient outcome.